
Assembly Biosciences (ASMB) Stock Forecast & Price Target
Assembly Biosciences (ASMB) Analyst Ratings
Bulls say
Assembly Biosciences Inc is advancing innovative therapeutic programs that target hepatitis B virus (HBV) infection and dysbiotic microbiomes, which positions the company well within the biotechnology sector. The firm is generating substantial revenue primarily from its HBV cure program, which includes promising drug candidates that demonstrate robust antiviral activity and the potential for peak sales of nearly $4 billion in the U.S. Moreover, recent clinical results and ongoing financial support, including a $175 million equity financing, indicate a strong likelihood of continued success and viability through at least 2027.
Bears say
Assembly Biosciences Inc continues to experience negative financial sentiment due to its long-standing history of operating losses and lack of established profitability. There are significant concerns surrounding the efficacy and safety of its drug candidates, particularly regarding potential negative outcomes for the ABI-6250 and ABI-1179/5366 programs, which may hinder advancement in clinical stages. Additionally, low virologic response rates, coupled with observations of adverse safety signals, contribute to a dim outlook for the company’s future revenue generation, primarily reliant on the success of its HBV-cure program.
This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Assembly Biosciences (ASMB) Analyst Forecast & Price Prediction
Start investing in Assembly Biosciences (ASMB)
Order type
Buy in
Order amount
Est. shares
0 shares